Table 2.
Respiratory function/disease severity, treatment and clinical outcomes by sex
| Sex |
||||
|---|---|---|---|---|
| Characteristics | Female | Male | p-valuea | Total |
| Respiratory function, median(IQR) | N = 77 | N = 197 | N = 274 | |
| Baseline PaO2/FiO2, mmHg | 254 (140, 336) | 191 (122, 294) | 0.02 | 216 (126, 302) |
| Respiratory rate, % | 22 (18, 28) | 22 (18, 28) | 0.89 | 22 (18, 28) |
| SOFA Score | 1 (0, 3) | 2 (0, 3) | 0.02 | 2 (0, 3) |
| Intervention, n(%) | N = 134 | N = 281 | 0.25 | N = 415 |
| Tocilizumab subcutaneous | 21 (16.8) | 50 (20.8) | 71 (19.5) | |
| Tocilizumab intravenous | 20 (16.0) | 25 (10.4) | 45 (12.3) | |
| SOC | 84 (67.2) | 165 (68.8) | 249 (68.2) | |
| Use of antibiotics, n(%) | N = 114 | N = 267 | N = 381 | |
| 10 (8.8) | 35 (13.1) | 45 (11.8) | ||
| Events, n(%) | N = 134 | N = 281 | N = 415 | |
| Invasive echanical ventilation (IMV) | 8 (6.0) | 58 (20.6) | <.001 | 66 (15.9) |
| Death - pre IMV | 15 (11.2) | 42 (14.9) | 0.30 | 57 (13.7) |
| Death - all | 19 (14.2) | 62 (22.1) | 0.06 | 81 (19.5) |
a
Chi-squared or Mann-Whitney test as appropriate.